Introduction
Methods
Review
Stearic acid in chocolate
Stearic Acid Observational Studies
Author | Year | No. Participants | Trial Design | Duration | Intervention | Outcome(s) |
---|---|---|---|---|---|---|
Kondo [83] | 1996 | 12 | Crossover | 1 meal, pre/post-meal measurement | Cocoa (35 g delipidated), vs. none | Decreased LDL oxidation |
Rein [138] | 2000 | 30 | Parallel | 1 meal, 2 & 6 hrs | Cocoa beverage (300 ml, 19 g procyanidin), caffeinated beverage (17 mg caffeine), or water | Decreased platelet activation, decreased platelet function |
Wang [79] | 2000 | 20 | Crossover | 1 meal, 1 week/phase | Procyanidin-rich chocolate (27, 53, 80 g), vs. none | Increased antioxidant capacity, decreased oxidative stress |
Osakabe [88] | 2001 | 15 | Parallel | daily, 2 weeks | Cocoa powder (36 g/day), vs. sugar | Decreased LDL oxidation (increased lag time) |
Wan [85] | 2001 | 23 | Crossover | daily, 4 weeks/phase | Cocoa powder (22 g/day) + dark chocolate (12 g/day), vs. average American diet | Decreased LDL oxidation (increased lag time), Increased HDL concentration |
Schramm [101] | 2001 | 10 | Crossover | 1 meal, 2 & 6 hrs, 1 week/phase | Chocolate (35 g, high 4 mg/g vs. low 0.09 mg/g procyanidin) | Increased prostacyclin, decreased leukotriene (likely decreased platelet activation, anti-inflammatory) |
Holt [95] | 2002 | 18 | Crossover | 1 meal, 2 hrs | Chocolate chips (25 g semi-sweet), vs. none | Decrease platelet function |
Mathur [86] | 2002 | 25 | Crossover | daily, 6 weeks/phase | Dark chocolate (37 g/day), cocoa powder (31 g/day), vs. none | Decreased LDL oxidizability, marginal HDL increase |
Pearson [92] | 2002 | 16 | Crossover | 1 meal, 1 day/phase | Cocoa beverage (300 ml, 19 g flavanol cocoa powder), cocoa beverage + aspirin, or aspirin | Decreased platelet activation, decreased platelet function, all additive of aspirin effects. |
Heiss [99] | 2003 | 20 | Crossover | 1 meal, 1 day/phase | Cocoa beverages (100 ml, high or low flavan-3-ol) | Increased NO bioactivity, improved endothelial function |
Innes [97] | 2003 | 30 | Parallel | 1 meal, 4 hrs | Dark (75% cocoa, highest flavonoid content), milk (20% cocoa), or white chocolate (no flavonoids) | Dark chocolate inhibited collagen-induced platelet aggregation |
Murphy [94] | 2003 | 32 | Parallel | daily, 28 days | Cocoa flavonoid tablets (234 mg), vs. placebo | Decreased platelet function, no difference oxidation status |
Serrafini [76] | 2003 | 12 | Crossover | 1 meal, 1 day/phase | Dark chocolate (100 g), dark chocolate (100 g) + milk (200 ml), or 200 g milk chocolate | Increase antioxidant capacity, in absence of milk |
Taubert [118] | 2003 | 13 | Crossover | daily, 14 days/phase | Dark chocolate (100 g, 500 mg polyphenols), vs. white chocolate (90 g, 0 mg polyphenols) | Lower systolic and diastolic blood pressure with dark chocolate |
Wiswedel [90] | 2004 | 20 | Crossover | 1 meal, 1 week washout | High flavanol (1.87 mg/ml) vs. low flavanol (0.14 mg/ml) cocoa beverage | Lower levels of lipid peroxidation indicators with high flavanol cocoa beverage |
Engler [98] | 2004 | 21 | Parallel | daily, 2 weeks | Chocolate (high vs. low flavonoid) | Improved endothelial function, no difference oxidative stress, lipids with high flavonoid choc. |
Mursu [115] | 2004 | 45 | Parallel | daily, 3 weeks | Dark chocolate, dark chocolate enriched with cocoa polyphenols, or white chocolate | Increased HDL concentration, no change LDL oxidizability |
Grassi [116] | 2005 | 15 | Crossover | daily, 15 days/phase | Dark chocolate (100 g, 500 mg polyphenols), vs. white chocolate (90 g, 0 mg polyphenols) | Lower systolic blood pressure, improved insulin sensitivity, lower insulin resistance |
Zhu [139] | 2005 | 8 | Parallel | 1 meal, 1–2–4–8 hrs | Cocoa beverage (high flavonoid); 0.25, 0.38, 0.50 g/kg body weight dose | Reduced susceptibility to free-radical induced hemolysis |
Vlachopoulos [140] | 2005 | 17 | Crossover | 1 meal, 1 day/phase | Dark chocolate (100 g, 2.62 g procyanidin), vs. none | Improved endothelial function, vasodilation of brachial artery, no change in blood pressure |
Fraga [119] | 2005 | 28 | Parallel | daily, 14 days | High flavanol milk chocolate (105 g, 168 mg flavanols) vs. low flavonoid chocolate (<5 mg flavanols) | Lower mean blood pressure, lower LDL cholesterol, lower oxidative stress markers in high flavanol chocolate group |
Author | Year | Study design | N, Population | Stearic acid assessment method | CHD/MI Outcomes | Other |
---|---|---|---|---|---|---|
Kromhout [141] | 1995 | Ecologic | 12,763 men, 16 cohorts of 7CS | Dietary intake | ↑ CHD mortality | |
Simon [68, 69] | 1995 | Prospective | 96 cases, 96 controls, USA-MRFIT | Serum levels | ↑ CHD incidence | Null-stroke incidence |
Watts [67] | 1996 | Prospective | 50 men, Australia | Dietary intake | ↑ CAD progression | |
Hojo [61] | 1998 | Case-control | 71 cases, 60 controls, Japan | Serum levels | Null-stenosis | |
Hu [65] | 1999 | Prospective | 80,082 women, USA-nurses | Dietary intake | ↑ CHD incidence | |
Yli-Jama [62] | 2002 | Case-control | 103 cases, 104 controls, Norway | Serum levels | ↓ MI incidence | |
Kabagambe [63] | 2003 | Case-control | 485 cases, 508 controls, Costa Rica | Dietary intake | ↑ MI incidence | |
Wang [66] | 2003 | Prospective | 3591 whites, USA | Serum levels | ↑ CHD mortality |
Flavonoids in chocolate
Mechanisms
Flavonoid Observational Studies
Author | Year | Study type | N, Population | Follow-up Years | Flavonoid Type | CHD/MI Incidence | CHD/MI Mortality | Stroke Mortality | Comments: |
---|---|---|---|---|---|---|---|---|---|
Hertog [125, 142]*, Keli [127] | 1993, 1996 | Prospective | 552 to 806 Men, Dutch | 5, then 10* | Total Flavonoids | ↓ | ↓ | ↓ | *Update 1997 analysis finds even stronger CHD association [142] |
Knekt [131] | 1996 | Prospective | 5133 M+W, Finland | 26 | Total Flavonoids | ↓ | |||
Rimm [123] | 1996 | Prospective | 34789 Men, USA | 6 | Total Flavonoids | Null | ↓* | *marginal significance, if past history of CVD | |
Hertog [133] | 1997 | Prospective | 1900 Men, UK | 14 | Total Flavonoids | Null | ↑* | *marginal significance, *milk consumed w/tea | |
Yochum [130] | 1999 | Prospective | 34492 PostM women, Iowa | 10 | Total Flavonoids | ↓ | Null | ||
Hirvonen [126, 129] | 2000, 2001 | Prospective | 23596 Men, Finland | 6.1 | Total Flavonoids | ↓ MI | ↓* | Null | *suggestive, but non-significant |
Arts [143] | 2001 | Prospective | 806 men, Dutch | 10 | Catechins (Flavonoid) | ↓ | Null | ||
Arts [128] | 2001 | Prospective | 34492 PostM women, Iowa | 13 | Catechins (Flavonoid) | ↓ | |||
Geleinjse [122] | 2002 | Prospective | 4807 M+W, Dutch | 5.6 | Total Tea Flavonoids | Null | ↓ | ||
Knekt [132] | 2002 | Prospective | 10054 M+W Finland | 28 | Specific flavonoids | ↓ | ↓ | also ↓ type 2 diabetes | |
Sesso [124] | 2003 | Prospective | 38445 women, USA | 6.9 | Total Flavonoids | Null | Null | Null | |
META-ANALYSIS (updated)**
|
Total Flavonoids → CHD Mortality
|
RR = 0.81 (95% CI: 0.71–0.92)*
|
(extreme tertiles)
|